Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

UNIVERSITY OF SYDNEY

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Established: 1850-01-01

Employees: -

Market Cap: -

Website: https://www.sydney.edu.au/

Clinical Trials

Better Evidence and Translation for Calciphylaxis

Phase 3

Recruiting

Conditions: Calciphylaxis

Interventions: Drug: Sodium Thiosulfate
Device: Medium Cut-off Dialyser
Device: High Flux Dialyser
Drug: Vitamin K1
Drug: Magnesium citrate
Drug: Placebo capsule (Vitamin K1)
Drug: Placebo injection (normal saline)
Drug: Placebo tablet (Magnesium citrate)

First Posted Date: 2021-08-24

Last Posted Date: 2024-06-21

Lead Sponsor: University of Sydney

Target Recruit Count: 350

Registration Number: NCT05018221

Locations: 🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Sunshine Coast Hospital and Health Service, Birtinya, Queensland, Australia

and more 11 locations

Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema

Not Applicable

Conditions: Macula Edema
Retinal Vein Occlusion

First Posted Date: 2021-04-19

Last Posted Date: 2021-04-19

Lead Sponsor: University of Sydney

Target Recruit Count: 14

Registration Number: NCT04847869

Locations: 🇦🇺
Macular Research Group, Save Sight Institute, The University of Sydney, Sydney, New South Wales, Australia

The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers

Phase 1

Completed

Conditions: SARS-CoV2 COVID-19

First Posted Date: 2021-02-08

Last Posted Date: 2023-10-30

Lead Sponsor: University of Sydney

Target Recruit Count: 68

Registration Number: NCT04742842

Locations: 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
🇦🇺
Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Adelaide, South Australia, Australia
🇦🇺
Wesfarmers Centre of Vaccines and Infectious Diseases Telethon Kids Institute, Perth, Western Australia, Australia

Nano-X Image Guidance: CBCT With Gravity-induced Motion

Early Phase 1

Not yet recruiting

Conditions: Cancer

First Posted Date: 2020-07-27

Last Posted Date: 2024-06-06

Lead Sponsor: University of Sydney

Target Recruit Count: 30

Registration Number: NCT04488224

Investigation of Respiratory-related Tumour Motion in Liver Cancer Patients Undergoing SBRT Using Audiovisual Biofeedback

Not Applicable

Completed

Conditions: Lung Cancer

First Posted Date: 2020-03-26

Last Posted Date: 2025-04-04

Lead Sponsor: University of Sydney

Target Recruit Count: 5

Registration Number: NCT04323618

Surface Monitoring Technology to Remove The Mask - Stage 1

Not Applicable

Recruiting

Conditions: Head and Neck Cancer
Radiation Therapy Complication
Anxiety

First Posted Date: 2020-02-12

Last Posted Date: 2024-07-09

Lead Sponsor: University of Sydney

Target Recruit Count: 20

Registration Number: NCT04266223

Locations: 🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

Phase 2

Active, not recruiting

Conditions: Glioblastoma Multiforme

Interventions: Drug: Nivolumab
Drug: Temozolomide

First Posted Date: 2019-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: University of Sydney

Target Recruit Count: 103

Registration Number: NCT04195139

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇦🇺
Campbelltown Hospital, Campbelltown, New South Wales, Australia
🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia

and more 17 locations

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Darolutamide
Drug: Placebo oral tablet
Drug: Luteinizing Hormone-Releasing Hormone Analog
Radiation: External Beam Radiotherapy

First Posted Date: 2019-10-23

Last Posted Date: 2023-07-28

Lead Sponsor: University of Sydney

Target Recruit Count: 1100

Registration Number: NCT04136353

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute - St. Elizabeth's, Brighton, Massachusetts, United States
🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States

and more 90 locations

Observational Study of Cardiovascular Disease.

Terminated

Conditions: Cardiovascular Morbidity
Cardiovascular Diseases
Coronary Heart Disease
Low-density-lipoprotein-type

First Posted Date: 2019-10-16

Last Posted Date: 2024-04-08

Lead Sponsor: University of Sydney

Target Recruit Count: 1137

Registration Number: NCT04128475

Locations: 🇺🇸
TIMI Study Group, Boston, Massachusetts, United States
🇳🇴
Oslo University Hospital, Nydalen, Oslo, Norway
🇬🇧
Imperial College London, London, United Kingdom

Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging

Not Applicable

Recruiting

Conditions: Lung Cancer

First Posted Date: 2019-09-11

Last Posted Date: 2024-01-11

Lead Sponsor: University of Sydney

Target Recruit Count: 30

Registration Number: NCT04086082

Locations: 🇦🇺
Alfred Health, Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy